University of Tennessee Health Science Center

Elevation Oncology Announces the Promotion of Valerie Malyvanh Jansen, M.D., Ph.D., to Chief Medical Officer

Retrieved on: 
Wednesday, October 20, 2021
Eli Lilly and Company, Biotechnology, Cancer, Seribantumab, University of Tennessee Health Science Center, Internal medicine, Private Securities Litigation Reform Act, COVID-19, Oncology, U.S. Securities and Exchange Commission, Growth, Vanderbilt University, Security (finance), Precision medicine, Goal, NRG1, Clinical research, Disease, Therapy, La Trobe Institute for Molecular Science, Doctor of Pharmacy, Neoplasm, Leadership, Nasdaq, Risk, Drug, Patient, Eli Lilly, University, ABIM, Forward-looking statement, Vanderbilt, Pharmacist, Company, Pharmaceutical industry, Medical imaging

"Dr. Jansen has made significant contributions to Elevation Oncology's vision since her arrival at the Company earlier this year and we are thrilled to have her take on this role within the Elevation Oncology executive team," said Shawn M. Leland, PharmD, RPh, Founder and Chief Executive Officer of Elevation Oncology.

Key Points: 
  • "Dr. Jansen has made significant contributions to Elevation Oncology's vision since her arrival at the Company earlier this year and we are thrilled to have her take on this role within the Elevation Oncology executive team," said Shawn M. Leland, PharmD, RPh, Founder and Chief Executive Officer of Elevation Oncology.
  • "Valerie has an extensive background in oncology and a deep understanding of precision medicine, and under her leadership, Elevation Oncology is well positioned for success.
  • Prior to joining Elevation Oncology, Dr. Jansen served as Executive Medical Director at Mersana Therapeutics, a clinical-stage biopharmaceutical company with a focus in oncology, where she led clinical development of antibody-drug conjugate therapies for patients living with cancer.
  • She completed residency in Internal Medicine and fellowship in Medical Oncology through the ABIM Physician-Scientist Research Pathway at Vanderbilt.

Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted for Virtual Poster Presentation at AACR-NCI-EORTC Virtual International Conference on Molecular Targets

Retrieved on: 
Tuesday, October 5, 2021
Therapy, Clinical trial, Cancer, University of Tennessee Health Science Center, CRPC, GTX, Chronic lymphocytic leukemia, Conference, Private Securities Litigation Reform Act, CVR, U.S. Securities and Exchange Commission, Hematological Cancer Research Investment and Education Act, Patient, AACR, SARD, ROR1, Prostate cancer, Venetoclax, Mantle cell lymphoma, CEO, University, Program, Center, Woman, Prostate, CLL, AR, Paclitaxel, SAN, Risk, MCL, Ewing's sarcoma, Drug development, Forward-looking statement, Nasdaq, Breast cancer, ETS, GLOBE, Pharmaceutical industry

Oncternal has conducted a series of preclinical studies in collaboration with the Center for Cancer Research at the University of Tennessee Health Science Center.

Key Points: 
  • Oncternal has conducted a series of preclinical studies in collaboration with the Center for Cancer Research at the University of Tennessee Health Science Center.
  • Oncternal intends to provide a programmatic update on ONCT-534 on its earnings call planned for early November 2021.
  • Oncternal cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements.
  • This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at Key Scientific Society Meeting

Retrieved on: 
Tuesday, September 14, 2021
Appropriation, U.S. Department of Defense Strategy for Operating in Cyberspace, CEO, BMI, FDA, University, Health, Forward-looking statement, Center, FAAP, U.S. Department of Veterans Affairs, Office of Inspector General, Adoption, BVA, ASM, University of Tennessee Health Science Center, Private Securities Litigation Reform Act, DXR, Defense, Blood volume, Risk, National Institutes of Health Clinical Center, Ultrafiltration, NIH, FAHA, Veterans' affairs, NYSE, Physician, Heart failure, MD, Volume overload, Heart Failure Society of America, Phenotype, Contract, Critical care, MPH, GLOBE, Anemia, Population, FHFS, Face, Diuresis, Veteran, SEC, FACC, National Institute, LVAD, Medical imaging, Medical device, Pharmaceutical industry

“The data we regularly collect on use of the BVA-100 test consistently demonstrates that it provides the most accurate and reliable methodology to both personalize and optimize treatment in heart failure patients,” added Mr. Feldschuh. “We are encouraged by the growing recognition of the significant value and clinical adoption of the BVA-100 test to improve both clinical and economic outcomes -- we look forward to providing updates on these outstanding results.”

Key Points: 
  • Volume-Guided Venous to Venous Ultrafiltration in Hospitalized Heart Failure Patients: This pilot study combined blood volume analysis and ultrafiltration to safely remove fluid with volume overload.
  • Study authors indicated that earlier utilization of the BVA-100 test may have prevented the acute renal injury from their previous diuresis.
  • This study also measures the benefit of the BVA-100 test for improving ambulatory heart failure patient care, a population that numbers more than 6 million in the U.S. alone.
  • Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation.

US Biologic® and BARDA DRIVe Partner to Develop Oral Flu Vaccines for Home Delivery

Retrieved on: 
Monday, August 9, 2021
Vaccine, Infection, Assistant, COVID-19 contracts in the United Kingdom, University of Tennessee Health Science Center, Drive, Gaps, Needle, Death, University, Partnership, HHS, BARDA, Public health, Biomedical Advanced Research and Development Authority, Influenza vaccine, Doctor of Philosophy, Syringe, Development, CDC, Therapy, Goal

MEMPHIS, Tenn., Aug. 9, 2021 /PRNewswire/ -- US Biologic todayannounces a partnership with BARDA DRIVe to develop oral influenza vaccines, increasing access to these life-saving technologies.

Key Points: 
  • MEMPHIS, Tenn., Aug. 9, 2021 /PRNewswire/ -- US Biologic todayannounces a partnership with BARDA DRIVe to develop oral influenza vaccines, increasing access to these life-saving technologies.
  • "Influenza vaccines should be easily accessible to everyone," says US Biologic CSO, Jolieke G. van Oosterwijk, PhD.
  • US Biologic CEO Mason Kauffman notes "Oral vaccines hold the potential to eliminate the need for needles and syringes, cold-chain logistics, and associated costs.
  • The company's proprietary oral-delivery platform is changing global disease prevention, allowing safe, effective, and cost-efficient delivery of vaccines and therapeutics.

University of Tennessee, Knoxville Expands Online Portfolio with Noodle to Include Masters of Public Health

Retrieved on: 
Wednesday, April 7, 2021
East Tennessee, Geography of Tennessee, Articles, Academic disciplines, Professional degrees of public health, Knoxville, Tennessee, University of Tennessee Health Science Center, University of Tennessee, Public health

KNOXVILLE, Tenn., April 7, 2021 /PRNewswire/ -- The University of Tennessee, Knoxville, is expanding its online portfolio with Noodle, the nation's fastest growing network of online learning, to include a Master of Public Health from the Department of Public Health in the College of Education, Health, and Human Sciences.

Key Points: 
  • KNOXVILLE, Tenn., April 7, 2021 /PRNewswire/ -- The University of Tennessee, Knoxville, is expanding its online portfolio with Noodle, the nation's fastest growing network of online learning, to include a Master of Public Health from the Department of Public Health in the College of Education, Health, and Human Sciences.
  • The online version of the Master of Public Health brings the same pedagogy, curriculum, and faculty expertise as the existing on-ground version.
  • Given the range of public health issues we face, there's never been a better time to take the program online.
  • "Public Health impacts all of our lives," says Thankam S. Sunil, Chairman of the Department of Health.

NCPDP Foundation Awards $100,000 Grant to UTHSC College of Pharmacy to Demonstrate Value of Physician/Pharmacist Collaboration Using PeCP

Retrieved on: 
Thursday, February 11, 2021
Health sciences, Health, National Council for Prescription Drug Programs, SCRIPT, University of Tennessee Health Science Center, Pharmacy, Prescription drug, Scottsdale, Arizona

We look forward to sharing the results of the research with our donors and the industry in the near future."

Key Points: 
  • We look forward to sharing the results of the research with our donors and the industry in the near future."
  • The project will leverage the strong relationship between researchers and practitioners at UTHSC College of Pharmacy, Mac's Pharmacy , FDS Inc. , and CometMD .
  • The NCPDP Foundation is a 501(c)(3) nonprofit charitable organization headquartered in Scottsdale, Arizona and is affiliated with the National Council for Prescription Drug Programs (NCPDP).
  • The NCPDP Foundation was established in December 2012 to support research, education, and charitable involvement within the healthcare industry.

Pippin Dental Care Announces Opening of New Office in Downtown Knoxville

Retrieved on: 
Tuesday, December 22, 2020
Dentist, Pediatric dentistry, Outline of dentistry and oral health, University of Tennessee Health Science Center, UCLA School of Dentistry, University of Pittsburgh School of Dental Medicine

Dr. William (Bill) Pippin said, "Since we moved our own residence to downtown Knoxville about six years ago, we recognized a need for a high-quality urban dental practice which also features esthetic offerings.

Key Points: 
  • Dr. William (Bill) Pippin said, "Since we moved our own residence to downtown Knoxville about six years ago, we recognized a need for a high-quality urban dental practice which also features esthetic offerings.
  • In addition to routine oral and dental care, the practice offers implants, orthodontics, periodontics, root canals, pediatric dentistry, extractions, IV sedation, and more.
  • Current Pippin Dental Care patients will continue to be served by the Sevierville office, but they may also make appointments at the new Marble City Dentistry & Facial Esthetics office if it is more convenient or preferable.
  • A native of Bristol, Tennessee, Dr. William Pippin graduated from the University of Tennessee, Knoxville, with a major in biology.

University of Tennessee Health Science Center and FDS, Inc. Form Partnership to Study the Impact of Community Pharmacy Driven COVID-19 Testing on Public Health

Retrieved on: 
Tuesday, August 25, 2020
Articles, University of Tennessee Health Science Center, Pharmacist, Pharmacy, Independent pharmacy

FORT WORTH, Texas, Aug. 25, 2020 /PRNewswire/ --FDS, Inc., a leading pharmacy software company, announced today a partnership with University of Tennessee Health Science Center (UTHSC) College of Pharmacy to mobilize community pharmacies as COVID-19 testing sites and to study the impact on public health.

Key Points: 
  • FORT WORTH, Texas, Aug. 25, 2020 /PRNewswire/ --FDS, Inc., a leading pharmacy software company, announced today a partnership with University of Tennessee Health Science Center (UTHSC) College of Pharmacy to mobilize community pharmacies as COVID-19 testing sites and to study the impact on public health.
  • Recent actions by U.S. Department of Health and Human Services authorize pharmacists, the nation's most accessible healthcare provider, to order and administer COVID-19 tests.
  • "This partnership will help community pharmacies across Tennessee, some in rural and medically underserved areas, provide vital access to COVID-19 testing that may otherwise not exist," said Kenneth Hohmeier, Associate Professor, Director of Community Affairs, University of Tennessee Health and Sciences Center.
  • The main campus in Memphis includes six colleges: Dentistry, Graduate Health Sciences, Health Professions, Medicine, Nursing, and Pharmacy.

UTHSC College of Pharmacy and AdhereHealth Partner to Help Underserved Communities During the COVID-19 Pandemic

Retrieved on: 
Tuesday, July 7, 2020
Health, Articles, University of Tennessee Health Science Center, Pharmacy, Pharmacist, Adherence

NASHVILLE, Tenn., July 7, 2020 /PRNewswire/ -- The University of Tennessee Health Science Center (UTHSC) College of Pharmacy has partnered with AdhereHealth , a leading medication adherence technology company, to help keep underserved communities healthy during the COVID-19 pandemic.

Key Points: 
  • NASHVILLE, Tenn., July 7, 2020 /PRNewswire/ -- The University of Tennessee Health Science Center (UTHSC) College of Pharmacy has partnered with AdhereHealth , a leading medication adherence technology company, to help keep underserved communities healthy during the COVID-19 pandemic.
  • Dr. Kenneth Hohmeier, associate professor and director of Community Affairs for the College of Pharmacy, said data shows that those who are suffering the most from COVID-19 in terms of death and morbidity are those in underserved communities.
  • Rose, CEO of AdhereHealth, said only about half of patients withchronicconditions take their medication as directed, even under normal circumstances.
  • "We're thrilled to support UTHSC College of Pharmacy and get more pharmacists out into the field as quickly as possible."

World Renowned Pediatric Rheumatologist and Immunologist Terri Finkel, M.D., Ph.D. Joins Le Bonheur Children's Hospital, St. Jude Children's Research Hospital and The University of Tennessee Health Science Center

Retrieved on: 
Thursday, May 7, 2020
University of Tennessee Health Science Center, Le bonheur, Finkel, Bonheur, Tennessee, University of Tennessee College of Medicine

Dr. Finkel will lead clinical, administrative, research and educational efforts at UTHSC in collaboration with Le Bonheur.

Key Points: 
  • Dr. Finkel will lead clinical, administrative, research and educational efforts at UTHSC in collaboration with Le Bonheur.
  • She will work at St. Jude to expand and manage partnerships with UTHSC and Le Bonheur Children's, facilitating joint visioning for programmatic growth.
  • "At Le Bonheur Children's, we are very excited to have Dr. Terri Finkel on board," said Le Bonheur Children's President and CEO Michael Wiggins, MBA, FACHE.
  • Richard S. Finkel, M.D., a pediatric neurologist married to Terri Finkel, will also join St. Jude, UTHSC and Le Bonheur Children's.